Toward understanding and exploiting tumor heterogeneity

By Ash A. Alizadeh, Victoria Aranda, A. Bardelli, C. Blanpain, Christoph Bock, C. Borowski, Carlos Caldas, Andrea Califano, Michael Doherty, Markus Elsner and 17 more. Nature Medicine, 2015

708 citations recorded by the source corpus.

The extent of tumor heterogeneity is an emerging theme that researchers are only beginning to understand. How genetic and epigenetic heterogeneity affects tumor evolution and clinical progression is unknown. The precise nature of the environmental factors that influence this heterogeneity is also yet to be characterized. Nature Medicine, Nature Biotechnology and the Volkswagen Foundation organized a meeting focused on identifying the obstacles that need to be overcome to advance translational research in and tumor heterogeneity. Once these key questions were established, the attendees devised potential solutions. Their ideas are presented here.

Subfields: Cancer Research, Molecular Biology, Radiology, Nuclear Medicine and Imaging

View Paper: https://www.semanticscholar.org/paper/038e0fa30d234c66fb1546607f94575fad0d7560

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

In Molecular Biology

In Radiology, Nuclear Medicine and Imaging

Citations in the corpus

Deep learning with multimodal representation for pancancer prognosis prediction (2019, background): “Next, the presence of inter-patient heterogeneity warrants that characterizing tumors individually is essential to improving the treatment process (Alizadeh et al. , 2015).”
SCENIC: Single-cell regulatory network inference and clustering (2017, background): “Standard clustering of the oligodendroglioma expression matrix resulted in clusters of cancer cells by the tumour of origin, similar to previous observations 55,57 (Figure 4a), due to strong inter-tumor heterogeneity 54 .”
A comparison of reference-based algorithms for correcting cell-type heterogeneity in Epigenome-Wide Association Studies (2017, positive): “One of the great challenges facing the omics community is that posed by intra-sample heterogeneity (ISH) [1].”
Precision Oncology: The Road Ahead (2017, background): “Therefore, the addition of epigenetics in clinical practice awaits the identification of epigenetic marks that mediate distinct tumor phenotypes of clinical relevance (such as mesenchymal differentiation, stemness, dormancy or therapy resistance) [65].”